Stroke is one of the main causes of disability among adults worldwide, with risk factors such as aging, hypertension, hyperglycemia, diabetes mellitus, and obesity.48, 49 The only FDA‐approved drug is tPA with limited treatment window and high risk of hemorrhagic transformation; hence, there is a significant need for finding a novel treatment for stroke. Here, PLAT is linked to obesity due to melanocortin 4 receptor deficiency.